Liver fibrosis scores couldbe used for predicting adverse outcomes in patients with STEMI

Post author:
Post published:January 29, 2024
Post category:uncategorized

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Liver fibrosis scores (LFSs) are novel tools for predicting cardiovascular events in patients with coronary artery disease.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

PacBio announces Kinnex RNA Kits, further scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA applications

Modified sugar molecules boost stem cell therapy for brain repair after cardiac arrest

Researchers find powerful combo weapon against aggressive lymphoma

Helpful Links

Subscribe To Us